Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a
dermatology therapeutics company developing medications for skin
diseases requiring medical interventions, today announced that Ted
White, Verrica President and CEO, will present a business overview
at the 20th Annual Needham Virtual Healthcare Conference on
Tuesday, April 13, 2021, at 8:45 a.m. ET.
Participants may access a live webcast of the event through the
The webcast can also be accessed in the Investors/Presentations
& Events section of the Verrica website at www.verrica.com. The
webcast replay will be available shortly after conclusion of the
event for 30 days.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing
medications for skin diseases requiring medical interventions.
Verrica’s late-stage product candidate, VP-102, is in development
to treat molluscum, common warts and external genital warts, three
of the largest unmet needs in medical dermatology. Verrica is also
developing VP-103, its second cantharidin-based product candidate,
for the treatment of plantar warts. The Company has also entered a
worldwide license agreement with Lytix Biopharma AS to develop and
commercialize LTX-315 for dermatologic oncology conditions. For
more information, Visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
A. Brian DavisChief Financial
Officer484.453.3300 ext. firstname.lastname@example.org